IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Examining the Usage of Dopamine Blockers in OCD Patients
This study has been completed.
Sponsor:
Sheba Medical Center
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00496925
First received: July 4, 2007
Last updated: January 31, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
We examine the usage of Dopamine blockers in OCD patients. We want to examine their frequency of usage, compare the course of the disease between those who receive and those who do not receive Dopamine blockers, and efficacy of the treatment.
The study will be done in two stages: 1. Collecting information the usage of Dopamine blockers from 150 OCD patients' files. 2. interviewing 60-70 patients to see the difference those who receive and those who do not receive Dopamine blockers in their current severity of disease.
| Condition |
|---|
| Obsessive Compulsive Disorder |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Examining the Usage of Dopamine Blockers in OCD Patients |
Resource links provided by NLM:
Further study details as provided by Sheba Medical Center:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Outpatient and Inpatients
Criteria
Inclusion Criteria:
- Patients over 18 years of age
- DSM-IV diagnosis of OCD
- Ability to understand patient information sheet, and consent to participate
Exclusion Criteria:
- Current or past Psychotic or Bipolar disorder
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00496925
Please refer to this study by its ClinicalTrials.gov identifier: NCT00496925
Locations
| Israel | |
| Chaim Sheba Medical Center | |
| Ramat-Gan, Israel, 52621 | |
Sponsors and Collaborators
Sheba Medical Center
Investigators
| Principal Investigator: | Joseph Zohar, MD | Chaim Sheba Medical Center |
More Information
| Responsible Party: | Prof. Joseph Zohar, Chaim Sheba Medical Center |
| ClinicalTrials.gov Identifier: | NCT00496925 History of Changes |
| Other Study ID Numbers: |
SHEBA- 07-4651-JZ-CTIL |
| Study First Received: | July 4, 2007 |
| Last Updated: | January 31, 2010 |
Additional relevant MeSH terms:
|
Compulsive Personality Disorder Obsessive-Compulsive Disorder Personality Disorders Mental Disorders Anxiety Disorders Dopamine Dopamine Antagonists Cardiotonic Agents |
Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on August 16, 2017